Abstract
5-10% of total prostate cancer (PCa) cases are hereditary. Particularly, immunocheckpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% PCa cases, whereas genetic susceptibility genes remain completely unknown. We identified a Chinese family with two PCa patients, in which the PCa phenotype co-segregated with a rare germline variant EGFRR831H. Patient-derived conditionally reprogrammed cells (CRC) exhibited increased EGFR and AKT phosphorylation, and a sensitivity to EGFR antagonist Afatinib in migration assays, suggesting the EGFR allele was constitutively active. Both EGFRR831H-mutant tumors contained biallelic CDK12 inactivation, together with prominent tandem duplication across the genome. These somatic mutations could be detected in urine before surgery. Analysis of public databases showed a significant correlation between mutation status of EGFR and CDK12. Taken together, our genetic and functional analyses identified a previously undescribed link between EGFR and prostate cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by grants from the Chinese Central Special Fund for Local Science and Technology Development of Hubei Province (2018ZYYD023), Science and Technology Department of Hubei Province Key Project (2018ACA159), and Wuhan Science and Technology Bureau Key Project (2018061005132294). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: This study was supported in part by grants from the Chinese Central Special Fund for Local Science and Technology Development of Hubei Province (2018ZYYD023), Science and Technology Department of Hubei Province Key Project (2018ACA159), and Wuhan Science and Technology Bureau Key Project (2018061005132294). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Disclaimers: The authors declare that they have no competing interests.
List of abbreviations
- BAF
- B-allele frequency
- COSMIC
- Catalogue of somatic mutations in cancer
- cfDNA
- Cell-free DNA
- CRC
- Conditionally reprogrammed cell
- CNV
- Copy-number-varied
- FFPE
- Formalin-fixed paraffin-embedded
- GWAS
- Genome-wide association studies
- IHC
- Immunohistochemistry
- ORF
- Open reading frame
- p-AKT
- Phosphorylated AKT
- p-EGFR
- Phosphorylated EGFR
- PCa
- Prostate cancer
- PI-RADS
- Prostate imaging reporting and data system
- PSA
- Prostate-specific antigen
- RT
- Room temperature
- SNV
- Short-nucleic-acid-variation
- TDP
- Tandem duplicator phenotype
- TCGA
- The cancer genome atlas
- VAF
- Variant allele frequency
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.